Stealth BioTherapeutics Inc.
This Phase 1, open-label trial will enroll approximately 6 subjects who have BTHS weighing between 7 and 30 kg. Subjects will receive a weight-based dose of elamipretide daily via SC injection for 4 weeks. PK samples will be collected on Day 1 and at week 4 to determine PK profile in BTHS patients weighing between 7 and 30kg.
In this Phase 1, open-label trial to evaluate the PK, safety, and tolerability of elamipretide, approximately 6 pediatric subjects with genetically confirmed BTHS weighing between 7 and 30 kg will be enrolled to receive daily dosing via SC injection for 4 weeks. To characterize the PK of elamipretide, PK sampling will be conducted at Day 1 and Week 4. The study is intended to characterize PK and safety across a broader range of body weights that haven't been studied in prior trials.
Inclusion Criteria: 1. Willing and able to provide signed informed consent form (ICF) prior to participation in any trial-related procedures. If applicable, informed consent in writing from parent(s) or legally-acceptable representative(s) and, informed assent from subject (if age appropriate according to local requirements) should be provided. 2. Agrees to adhere to the trial requirements for the length of the trial. 3. Must have genetically confirmed Barth Syndrome (pathogenic variant in the TAZ gene) 4. Male aged ≥ 1 year and weighing between 7 and 30 kg at time of the Baseline Visit 5. Fo…
SC injection daily